Apples to Apples: Playing the Comparability Game in Biotherapeutics Development

Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk.

Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to get important insights and recommendations on how to successfully plan your clinical and CMC manufacturing development plans to reduce your regulatory risk along the way.

Learning Points

  • The importance of comparability studies for biologics
  • Key aspects of a comparability assessment
  • How to determine analytical and stability parameters when measuring comparability
  • Conditions for evaluating stability studies



Meet Veristat. Learn More.

2 min read

Unlock the Secrets of Effective SD File Preparation for FDA Submissions

In today's world where digital transformation is reshaping industries, even the pharmaceutical sector is not immune to...

10 min read

Regulatory Guidance Monthly Review - August 2023

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US...